SEC Comment Letter for Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Oct 2, 2017
Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: Oct. 2, 2017 · CIK: 0001536196 · Accession: 0000000000-17-034986
AI Filing Summary & Sentiment
Reasoning
Letter
October 2, 2017 Dr. Pnina Fishman Chief Executive Officer Can-Fite BioPharma Ltd. 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, Israel Can-Fite BioPharma Ltd. Registration Statement on Form F-3 Filed September 26, 2017 File No. 333-220644Re: Dear Dr. Fishman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Gary Emmanuel
Show Raw Text
October 2, 2017 Dr. Pnina Fishman Chief Executive Officer Can-Fite BioPharma Ltd. 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, Israel Can-Fite BioPharma Ltd. Registration Statement on Form F-3 Filed September 26, 2017 File No. 333-220644Re: Dear Dr. Fishman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Gary Emmanuel